In this issue:
Treatment practices for BRAFV600E mutant metastatic CRC in Europe
RNF43 mutations predict response to targeted combos in MSS BRAFV600E mutated CRC
Higher ADR reduces risk for post-colonoscopy CRC in FIT-positive patients
Increased use of neoadjuvant CRT improves survival in stage 2/3 rectal cancer
Improvement in CRC outcomes is limited to patients with left-sided disease
A liquid biopsy signature for the detection of patients with early-onset CRC
Napabucasin fails to prolong survival in advanced metastatic disease
Prognostic factors for outcomes after TARE in metastatic CRC
Complications after TME for rectal cancer impair recovery and survival
Sarcopenia impacts survival after surgery for middle/lower rectal cancer
Please login below to download this issue (PDF)